

APAS® INDEPENDENCE PRESENTED AT AMERICAN SOCIETY FOR MICROBIOLOGY ANNUAL CONFERENCE

Thermo Fisher Scientific showcase APAS® Independence at ASM Microbe 2023, 16-18 June

Adelaide, Australia, 20 June 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT or the Company**), a leader in microbiology automation using artificial intelligence, is pleased to announce the Company's APAS® Independence product was presented at the annual ASM Microbe (American Society for Microbiology) conference held in Texas, USA (16 – 18 June 2023).

Key Points:

- **APAS® Independence instrument displayed on Thermo Fisher Scientific booth at ASM Microbe 2023**
- **Dedicated symposium session highlights laboratory efficiencies gained through automated plate reading**
- **Dr Mary George shares experience implementing APAS® technology at Albany Medical Center**
- **Negative urine cultures reported 2 hours earlier through APAS® automated reporting of results**

The annual ASM Microbe conference is the largest microbial sciences conference held each year in the United States, featuring the latest scientific publications and innovations in microbiology. The conference is attended by leading microbiologist from around the world and provides an important opportunity to showcase the latest technologies. During this year's conference, the APAS® Independence was presented to attendees by Thermo Fisher Scientific (**Thermo Fisher**), with the instrument displayed as the central attraction on their exhibition booth.

The APAS® Independence also featured prominently within the scientific program, with the publication of new clinical data highlighting the potential efficiencies and improvements to reporting timeframes gained by laboratories through the implementation of automated culture plate reading. This included a dedicated symposium session presented by Dr Mary George (Microbiology Director at Albany Medical Center, New York, USA), who shared her experiences implementing the APAS® technology within her laboratory.

LBT Scientific Director, Dr Steven Giglio said:

“The data presented at this year’s ASM Microbe conferences demonstrates a shift in maturity for our APAS® technology, where laboratories are presenting data not only highlighting the accuracy of the APAS® Independence to read plates, but now having data demonstrating the positive impact this has on laboratory workflows and turnaround times for reports. This offers a huge benefit to laboratories that continue to suffer with chronic staffing shortages and increasing laboratory workloads.”

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence in the United States and selected countries in Europe.

INVESTOR ENQUIRIES**LBT Innovations****Brent Barnes**

Chief Executive Officer & Managing Director

Tel: +61 8 8227 1555

E: info@lbtinnovations.com